A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Not all companies are created equal, and StockStory is here to surface the ones with real upside. Keeping that in mind, here are three cash-producing companies that don’t make the cut and some better opportunities instead.
Himax (HIMX)
Trailing 12-Month Free Cash Flow Margin: 8.6%
Taiwan-based Himax Technologies (NASDAQ: HIMX) is a leading manufacturer of display driver chips and timing controllers used in TVs, laptops, and mobile phones.
Why Should You Sell HIMX?
- Sales tumbled by 4.2% annually over the last five years, showing market trends are working against it during this cycle
- Sales were less profitable over the last five years as its earnings per share fell by 22% annually, worse than its revenue declines
- High net-debt-to-EBITDA ratio of 8× increases the risk of forced asset sales or dilutive financing if operational performance weakens
At $14.25 per share, Himax trades at 2.6x forward price-to-sales. Check out our free in-depth research report to learn more about why HIMX doesn’t pass our bar.
Royal Caribbean (RCL)
Trailing 12-Month Free Cash Flow Margin: 7.5%
Established in 1968, Royal Caribbean Cruises (NYSE: RCL) is a global cruise vacation company renowned for its innovative and exciting cruise experiences.
Why Do We Think RCL Will Underperform?
- Demand for its offerings was relatively low as its number of passenger cruise days has underwhelmed
- Free cash flow margin is on track to jump by 1.2 percentage points next year, meaning the company will have more resources to pursue growth initiatives, repurchase shares, or pay dividends
- Below-average returns on capital indicate management struggled to find compelling investment opportunities
Royal Caribbean’s stock price of $285.13 implies a valuation ratio of 16.4x forward P/E. If you’re considering RCL for your portfolio, see our FREE research report to learn more.
Baxter (BAX)
Trailing 12-Month Free Cash Flow Margin: 6.4%
With a history dating back to 1931 and products used in over 100 countries, Baxter International (NYSE: BAX) provides essential healthcare products including dialysis therapies, IV solutions, infusion systems, surgical products, and patient monitoring technologies to hospitals and clinics worldwide.
Why Are We Out on BAX?
- Weak constant currency growth over the past two years indicates challenges in maintaining its market share
- Sales over the last five years were less profitable as its earnings per share fell by 7.2% annually while its revenue was flat
- Push for growth has led to negative returns on capital, signaling value destruction
Baxter is trading at $21.81 per share, or 11.5x forward P/E. Dive into our free research report to see why there are better opportunities than BAX.
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
